Research programme: nitric oxide-donating therapeutics - NicOx/Merck
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Merck & Co; NicOx
- Class
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Unspecified
- Discontinued Hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in France (PO)
- 15 Sep 2010 Discontinued - Phase-I for Hypertension in USA (PO)